| 11224601 |
Compounds that inhibits MCL-1 protein |
Paul E. Harrington, Kate Ashton, Sean P. Brown, Matthew R. Kaller, Todd J. Kohn +7 more |
2022-01-18 |
$641,433,000 |
| 10821115 |
Compounds that inhibit Mcl-1 protein |
Paul E. Harrington, Kate Ashton, Sean P. Brown, Matthew R. Kaller, Todd J. Kohn +7 more |
2020-11-03 |
$280,862,000 |
| 10632128 |
Compounds that inhibit Mcl-1 protein |
Paul E. Harrington, Kate Ashton, Sean P. Brown, Matthew R. Kaller, Todd J. Kohn +7 more |
2020-04-28 |
$393,385,000 |
| 10500213 |
Compounds that inhibit Mcl-1 protein |
Sean P. Brown, Kexue Li, Yunxiao Li |
2019-12-10 |
$651,177,000 |
| 10300075 |
Compounds that inhibit MCL-1 protein |
Sean P. Brown, Kexue Li, Yunxiao Li |
2019-05-28 |
$208,028,000 |
| 9550762 |
Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
Jennifer R. Allen, Albert Amegadzie, Matthew P. Bourbeau, James Brown, Jian Chen +21 more |
2017-01-24 |
$492,282,000 |
| 9066954 |
Fused heterocyclic derivatives and methods of use |
Brian K. Albrecht, David Bauer, Steven Bellon, Christiane M. Bode, Shon Booker +16 more |
2015-06-30 |
$523,879,000 |
| 8642624 |
Substituted alkylamine derivatives and methods of use |
Guoqing Chen, Jeffrey Adams, Jean E. Bemis, Shon Booker, Guolin Cai +18 more |
2014-02-04 |
$245,061,000 |
| 8524900 |
Fused heterocyclic derivatives and methods of use |
Brian K. Albrecht, David Bauer, Christiane M. Bode, Shon Booker, Alessandro Boezio +13 more |
2013-09-03 |
$488,028,000 |
| 8431563 |
Compounds that interact with glucokinase regulatory protein for the treatment of diabetes |
Kate Ashton, Michael D. Bartberger, Yunxin Y. Bo, Marian C. Bryan, Michael Croghan +12 more |
2013-04-30 |
$350,213,000 |
| 8314087 |
Nitrogen-containing heterocyclyl ketones and methods of use |
Brian K. Albrecht, Steven Bellon, Shon Booker, Alan C. Cheng, Derin D'Amico +8 more |
2012-11-20 |
$85,243,000 |
| 7820665 |
Imidazopyridazine inhibitors of PI3 kinase for cancer treatment |
Shon Booker, Tae-Seong Kim, Hongyu Liao, Longbin Liu, Mark H. Norman +2 more |
2010-10-26 |
$81,898,000 |
| 7524874 |
Vanilloid receptor ligands and their use in treatments |
Elizabeth M. Doherty, Jiawang Zhu, Mark H. Norman, Vassil I. Ognyanov, Christopher H. Fotsch +6 more |
2009-04-28 |
$107,879,000 |
| 7396831 |
Vanilloid receptor ligands and their use in treatments |
Elizabeth M. Doherty, Jiawang Zhu, Mark H. Norman, Vassil I. Ognyanov, Christopher H. Fotsch +6 more |
2008-07-08 |
$349,169,000 |
| 7332511 |
Vanilloid receptor ligands and their use in treatments |
Elizabeth M. Doherty, Jiawang Zhu, Mark H. Norman, Hui-Ling Wang, Christopher H. Fotsch +10 more |
2008-02-19 |
$151,558,000 |
| 7301022 |
Vanilloid receptor ligands and their use in treatments |
Yunxin Y. Bo, Partha Chakrabarti, Ning Chen, Hongyu Liao, Mark H. Norman +2 more |
2007-11-27 |
$320,974,000 |
| 7148221 |
Vanilloid receptor ligands and their use in treatments |
Elizabeth M. Doherty, Jiawang Zhu, Mark H. Norman, Hui-Ling Wang, Christopher H. Fotsch +10 more |
2006-12-12 |
$180,493,000 |
| 7144888 |
Vanilloid receptor ligands and their use in treatments |
Elizabeth M. Doherty, Jiawang Zhu, Mark H. Norman, Hui-Ling Wang, Christopher H. Fotsch +10 more |
2006-12-05 |
$91,213,000 |
| 7115607 |
Substituted piperazinyl amides and methods of use |
Christopher H. Fotsch, Premilla Arasasingham, Yunxin Y. Bo, Ning Chen, Martin Goldberg +9 more |
2006-10-03 |
$147,958,000 |
| 7053088 |
Vanilloid receptor ligands and their use in treatments |
Elizabeth M. Doherty, Jiawang Zhu, Mark H. Norman, Vassil I. Ognyanov, Christopher H. Fotsch +6 more |
2006-05-30 |
$161,240,000 |
| 6995162 |
Substituted alkylamine derivatives and methods of use |
Guoqing Chen, Jeffrey Adams, Jean E. Bemis, Shon Booker, Guolin Cai +18 more |
2006-02-07 |
$507,165,000 |